share price, page-56

mate cardiocel which ahz is applying for ce mark is currently in use, in children for congential heart defects, 10 years of trials, superior to current gold standard heart patches in use and 4 years on in some patients no calcification whereby current patches find calicification and hardening with weeks or days, it also has twiggy as its major holder just upping his stake by 2% to 17% at 5c just 2 weeks ago, nothing is guaranteed and i never said so, some will wait for technical approval to buy in, add to this a mc of 55m, 8m pa revenue from infusion business and 100% success rate on mice with frazer herpes vaccine, you tell me there not undervalued when ahz isn't a 1 product coy valued at 55m? not cross promoting but i have to give a bit of insight into my decisions, i hope prr doesn't go up and i miss out, but i have to state my reasons honestly without it being a downramp, anywho, thats enough on me for this, good luck